Old Brains, Young Brains, Same Smoke: Why Cannabis Cools Inflammation in Aged Mice but Stokes It in Young Ones

Key Takeaways

• Aging mice show widespread cytokine elevation across blood, hippocampus, cortex
• Cannabis smoke lowered IL‑13 and Dkk1 in old mice hippocampus only
• Same exposure raised those markers in young mice hippocampus
• No significant inflammation changes observed in blood or prefrontal cortex
• Findings caution against using cannabis as anti‑inflammatory for youth

Pulse Analysis

Inflammaging—low‑grade, chronic inflammation that escalates with age—is a well‑documented driver of cognitive decline and neurodegenerative disease. As baby‑boomers turn to cannabis for pain, sleep and anxiety, the scientific community has largely relied on cell‑culture or injection studies in young rodents to claim anti‑inflammatory benefits. This gap left clinicians uncertain whether inhaled cannabis, the most common consumption route, truly modulates the inflammatory milieu of an aging brain.

The UF team addressed the gap by delivering realistic cannabis smoke (≈6 % THC) to both young and old mice using an automated smoking apparatus. Across all tissues, aged mice displayed markedly higher cytokine levels, confirming that age alone reshapes immune signaling. The standout finding was the hippocampal response: in older mice, cannabis reduced two age‑linked markers, IL‑13 and Dkk1, whereas the same exposure increased them in younger mice. Blood and prefrontal cortex showed only modest, non‑directional shifts, underscoring the region‑specific nature of the effect.

These results temper enthusiasm for cannabis as a universal anti‑inflammatory agent. For older adults, the hippocampal anti‑inflammatory signal is narrow, smoke‑derived, and unlinked to functional outcomes. For younger individuals, the opposite pro‑inflammatory trend raises safety concerns. Researchers and drug developers should therefore prioritize age‑stratified studies and explore non‑combustion delivery methods before translating these findings into clinical recommendations. Until longer‑term behavioral and lifespan data emerge, restraint remains the prudent stance for both consumers and clinicians.